Sun Pharmaceutical reported a 10.5% rise in quarterly revenue to ₹15,300 crore, supported by strong Indian formulations and global specialty product growth. While the domestic business continues to lead with an 8.4% market share, EBITDA margins moderated to 28.1% compared to the previous year. Investors are now tracking the company’s ability to sustain high single-digit revenue growth and the impact of newer product launches on future profitability.
Quarterly Financial Performance
Sun Pharmaceutical Industries reported its financial results for the first quarter of fiscal year 2027, highlighting a 10.5% year-on-year increase in revenue from operations, which reached ₹15,300 crore. This growth was largely supported by solid demand in its India formulations business and continued momentum in the company’s global Innovative Medicines portfolio. The company’s EBITDA for the quarter rose 5.5% year-on-year to ₹4,296 crore.
Growth Drivers and Portfolio
The company’s global specialty business, which accounts for approximately 22% of total sales, continues to play a significant role in its growth strategy. Established products like ILUMYA and ODOMZO remain key contributors to this segment, while newer launches such as Leqselvi and Unloxcyt are gradually gaining market traction. In the domestic market, Sun Pharma maintains a leadership position with an 8.4% market share. This domestic strength is driven by a combination of higher sales volumes and the consistent introduction of new products. For the full year, the company has indicated an expectation of high single-digit business growth, with both the specialty portfolio and domestic market expected to remain the primary drivers.
Understanding Margin Moderation
While revenue showed double-digit growth, the company’s EBITDA margin moderated to 28.1% during the quarter. This dip in profitability compared to the previous year is largely attributed to the absence of the one-time benefit from Lenalidomide sales that supported profitability in Q1FY26. While this shift reflects a tougher comparison base rather than a fundamental decline in operations, it underscores the importance of the company's newer specialty products in contributing to long-term profitability. Investors watching the stock should look at whether the company can maintain its projected revenue growth and whether profit margins begin to stabilize as the base effect from older one-off product sales fades.
Analyst Perspective
Following the results, Geojit Financial Services maintained its positive view on the stock, revising its target price to ₹2,070, based on a valuation of 30 times estimated adjusted earnings per share for FY28. The brokerage's assessment is rooted in the company's continued domestic leadership and the successful scaling of its newer specialty portfolio. The most important factor for shareholders to monitor in the coming quarters will be the execution of these specialty drug launches and the company’s ability to manage its operating costs to protect profit margins against potential volatility.